# Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

> **NCT00840671** · PHASE3 · COMPLETED · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 119 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Cerebrolysin
- **DRUG:** 0.9% Saline Solution

## Key facts

- **NCT ID:** NCT00840671
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-03
- **Final completion:** 2008-07
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2010-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840671, "Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00840671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*